Introduction
============

Oligo-oxa-adamantanes are rarely found in nature as structurally striking biochemicals. The neurotoxic sodium channel blocker tetrodotoxin (TTX), one of the most toxic non-proteinaceous poisons along with aconitine, veratridine, saxitoxin (STX), batrachotoxin (BTX) and palytoxin (PTX), is widely spread in nature, especially in marine ecosystems. TTX, traditionally esteemed famous for its occurrence in the inner organs (especially liver and ovaries) of the Japanese culinaric delicacy *tora fugu*, the globe (tiger puffer) fish *Spheroides rubripes* (*Tetraodontidae*), is to be depicted as substituted 2,8-dioxa-adamantane[@BIB1] ([Fig. 1](#FIGGR1){ref-type="fig"} ).[@BIB1], [@BIB2], [@BIB3] Daigremontianin was isolated from the tropical flower *Kalanchoe daigremontiana* Hamet *et* Perr. (*Crassulaceae*) and was shown to be a steroid (bufadienolide) 2,8,9-trioxa-adamantane ([Fig. 1](#FIGGR1){ref-type="fig"}).[@BIB4], [@BIB5] Synthetic adamantanes, or tricyclo\[3.3.1.1^3,7^\]decanes, are used as antiviral chemotherapeutics \[amantadine (1-amino-adamantane) and rimantadine systemically against influenza A virus, tromantadine topically against herpes simplex virus type 1 infections\] and antiparkinsonian (muscle relaxant) drugs \[amantadine as central dopaminergic, memantine (1-amino-3,5-dimethyl-adamantane) as neuroprotective *N*-methyl-[d]{.smallcaps}-aspartate (NMDA)-subtype glutamate receptor antagonist\] ([Fig. 1](#FIGGR1){ref-type="fig"}).Figure 1The natural products tetrodotoxin and daigremontianin with oligo-oxa-adamantane structure and the synthetic adamantanes, or tricyclo\[3.3.1.1^3,7^\]decanes, amantadine, rimantadine, tromantadine, and memantine.

In addition to the *Schiff* base[@BIB6] formation of pyridoxal (mainly existing as racemic cyclic hemiacetal, especially as hydrochloride) and pyridoxal 5′-phosphate (coenzyme vitamin B~6~) with primary amino groups of biomolecules which is of central importance in coenzyme vitamin B~6~-catalyzed biochemical metabolism (transamination, decarboxylation, racemization, ligation, lysis) of amino acid, neurotransmitter, phospholipid, sphingolipid, heme, polyamine and tumor marker[@BIB7] synthesis, pyridoxal and pyridoxal 5′-phosphate are capable of undergoing various chemical reactions. Especially *Knoevenagel* condensations lead to interesting compounds with antiretroviral, oncolytic, immunosuppressant, antioxidative, free radical-scavenging, nitric oxide synthase inhibition and other biological activities.[@BIB8], [@BIB9], [@BIB10], [@BIB11], [@BIB12] Recently, a new conception for inducing selective apoptosis in human immunodeficiency virus type 1 (HIV-1)-infected cells was proposed.[@BIB12] Therefore, my attention focused on the analysis of unique reactions of vitamin B~6~ which was shown to be suitable for various chemical transactions.[@BIB8], [@BIB9], [@BIB10], [@BIB11], [@BIB12]

Results and discussion
======================

Infrared absorption spectroscopy of the reaction product resulting from the heat and hydrochloric acid treatment of pyridoxylidenephloroglucinol
------------------------------------------------------------------------------------------------------------------------------------------------

An infrared absorption (IR) spectrum of the reaction product was recorded in a solid potassium bromide (KBr) pellet ([Fig. 2](#FIGGR2){ref-type="fig"} ). No α,β-unsaturated, quinoid carbonyl absorption at wavenumbers between 1700 and 1600 cm^−1^ could be seen. Instead a very broad OH band between 3650 and 1800 cm^−1^ dominates the IR spectrum. It represents a valence bond vibration of hydrogen-bonded O--H, and, respectively, intra/intermolecular polymeric associated chelate O--H. At 2900 cm^−1^ a methyl group C--H and at 2825 cm^−1^ a methylene group C--H valence bond vibration can be identified. At 1590 and 1520 cm^−1^ C--C aromatic valence bond vibrations of a pyridine heterocycle can be detected. At wavenumbers of 1430 cm^−1^ a methylene C--H deformation vibration and 1395 cm^−1^ a methyl group C--H deformation vibration can be analyzed. Very characteristic is the aromatic C--O phenolic valence bond vibration at 1210 cm^−1^. The two bands at 1065 cm^−1^ (Ar--CH~2~--OH) and 1110 cm^−1^ are aliphatic C--O valence bond vibrations. The absorption band at 820 cm^−1^ is fitting to a 1,2,3,4-tetrasubstituted aromate with one isolated CH. Taken together, already the IR data unequivocally proof the unusual 1-\[3-hydroxy-5-(hydroxymethyl)-2-methyl-4-pyridinyl\]-2,8,9-trioxaadamantane-3,5,7-triol structure because the 6-hydroxy-4-(hydroxymethyl)-1-methyl-8*H*-[@BIB1]benzopyrano\[2,3-c\]pyridin-8-one alternative would have a strong α,β-unsaturated, quinoid carbonyl absorption between wavenumbers of 1775 and 1650 cm^−1^ (preferably 1650--1700 cm^−1^, *p*-benzoquinone 1669 cm^−1^). The predominant, very broad OH band from 3650 to 1800 cm^−1^ peaking at 3350 cm^−1^ pointed to strongly associated intermolecular hydrogen bonds in the solid state of the brown substance KBr pellet. A similar effect was observed in the IR spectrum (in KBr) of the polyhydroxyl, solvent-retaining compound tetrodotoxin.[@BIB3] Figure 2Infrared (IR) absorption spectrum measured in potassium bromide (KBr) solid disc of the unknown brown-black reaction product resulting from the heat and hydrochloric acid treatment of pyridoxylidenephloroglucinol.

UV spectrophotometry of the reaction product resulting from the heat and hydrochloric acid treatment of pyridoxylidenephloroglucinol
------------------------------------------------------------------------------------------------------------------------------------

An UV electronic absorption spectrum of the substance was recorded in 0.1 M sodium hydroxide solution ([Fig. 3](#FIGGR3){ref-type="fig"} ). The solubility of the material in water, ethanol, or dilute acid \[dilute hydrochloric (HCl) and sulfuric acid (H~2~SO~4~)\] is too low to work in these solvents. The product is soluble in sodium hydroxide solution and dimethyl sulfoxide (DMSO) to give yellow to brown solutions. The UV spectrum showed two maxima at 220.0 nm (ε=22,443 L mol^−1^ cm^−1^) and 285.8 nm (ε=11,591 L mol^−1^ cm^−1^), the molar mass for the calculation of the molar extinction coefficient *ε* was choosed as *M*=327.29 g/mol, the theoretic molar mass of 1-\[3-hydroxy-5-(hydroxymethyl)-2-methyl-4-pyridinyl\]-2,8,9-trioxaadamantane-3,5,7-triol ([Fig. 3](#FIGGR3){ref-type="fig"}). This result can be reasonably interpreted in the way that a typical sodium phenolate \[sodium phenolate in water: λ~1,max~=235 nm (ε=9400), λ~2,max~=287 nm (ε=2600)\] is the chromophor of the compound. The structure 6-hydroxy-4-(hydroxymethyl)-1-methyl-8*H*-\[1\]benzopyrano\[2,3-c\]pyridin-8-one would show an electronic absorption maximum at a wavelength of approximately 450 nm similar to the α,β-unsaturated carbonyl condensate B6PR.[@BIB11] Therefore, the UV spectrophotometry supplies us with strong evidence for 1-\[3-hydroxy-5-(hydroxymethyl)-2-methyl-4-pyridinyl\]-2,8,9-trioxaadamantane-3,5,7-triol to represent the UV chromophor of the unknown product. Already now the spectral-analytic structure determination provides growing proof for being 1-\[3-hydroxy-5-(hydroxymethyl)-2-methyl-4-pyridinyl\]-2,8,9-trioxatricyclo\[3.3.1.1^3,7^\]decane-3,5,7-triol the suspected structural composition of the material in question.Figure 3UV electronic absorption spectrophotometry of the unknown brown-black reaction product resulting from the heat and hydrochloric acid treatment of pyridoxylidenephloroglucinol. For this purpose, 0.70 mg substance were dissolved in an 100.00 mL volume of 0.1 M sodium hydroxide (NaOH) solution. The maximal absorption of the yellow solution stayed in the linear range of the spectrophotometer (*A* \<0.8).

Proton nuclear magnetic resonance (^1^H NMR) spectroscopy of the reaction product resulting from the heat and hydrochloric acid treatment of pyridoxylidenephloroglucinol
-------------------------------------------------------------------------------------------------------------------------------------------------------------------------

The final structural proof could be made by examination of the ^1^H NMR spectrum of the substance in deuterated chloroform (CDCl~3~) ([Fig. 4](#FIGGR4){ref-type="fig"} ). At the chemical shift δ 2.50 a singlet of three protons of the heteroaromatic methyl group peaked. At δ 3.32 six protons of the methylene groupings of the trioxa-adamantane-triol could be unequivocally identified. At δ 4.85 (m, 2H, pyridine C*H* ~2~OH) and δ 5.90 (m, 1H, CH~2~O*H*) the intermolecular-associated hydroxymethyl group gave broadened multiplets emerging possibly from interaromatic charge-transfer complexation and hydrogen-bonding. At δ 8.11 one heteroaromatic proton proofed to complete that no other structural composition was possible than 1-\[3-hydroxy-5-(hydroxymethyl)-2-methyl-4-pyridinyl\]-2,8,9-trioxatricyclo\[3.3.1.1^3,7^\]decane-3,5,7-triol. Ethanol, water, and the educt pyridoxylidenephloroglucinol were detectable as trace impurities from synthesis.Figure 4^1^H NMR spectrum of bananin in CDCl~3~. The bananin contained as impurities the synthesis solvents ethanol \[δ 1.18 (t), 3.59 (q)\] and water \[in CDCl~3~ δ 1.28 (s)\]. Additionally, traces of the synthesis educt pyridoxylidenephloroglucinol \[δ 2.70 (s, C*H*~3~), 5.37 (d, C*H*~2~OH), 6.42 (s, HO--CC*H*--CO), 6.60 (s, HO--CC*H*--CO), 7.13 (s, arC*H*R), 8.89 (s, pyridine C*H*)\] were detectable.

Conclusion
==========

Structural, supramolecular and physicochemical aspects of BN
------------------------------------------------------------

Since the organic chemical structure of the material resulting from the heat and hydrochloric acid treatment of pyridoxylidenephloroglucinol could be defined by the analytical results, an experimentally based scheme for the chemical reactions leading to the synthesis of 1-\[3-hydroxy-5-(hydroxymethyl)-2-methyl-4-pyridinyl\]-2,8,9-trioxatricyclo\[3.3.1.1^3,7^\]decane-3,5,7-triol is depicted ([Fig. 5](#FIGGR5){ref-type="fig"} ). The hypothesis that bananin is an highly intermolecular-associated material, leading to a nearly black colour through interaromatic charge-transfer complexation between the pyridine heterocycles and hydrogen-bonding between the trioxa-adamantane-triol heterotricycles is supported by combination of the IR, UV, and ^1^H NMR data ([Fig. 6](#FIGGR6){ref-type="fig"} ). An instruction protocol for the isolation of amorphous bananin picrate was developed. Amorphous bananin picrate is soluble in water with intense yellow colour and liberates brown-black amorphous bananin by treatment with strong bases (NaOH solution). The intermolecular network leading to the black colour of bananin is interrupted in the yellow bananin picrate ([Fig. 6](#FIGGR6){ref-type="fig"}) by complexing the pyridine heterocycle with picric acid. Furthermore, a sodium hydroxide-containing solution of bananin monosodium salt in water both forms a blue copper complex with Cu(OH)~2~ and a white zinc complex with Zn(OH)~2~. It is proposed that bananin behaves as bidentate chelate donor to build the tetragonal-planar coordination complex (*SP-4-1*)-bis\[1-\[3-hydroxy-5-(hydroxymethyl)-2-methyl-4-pyridinyl\]-2,8,9-trioxaadamantane-3,5,7-triolato(1-)-*O* ^2^,*O* ^3'^\]copper ([Fig. 7](#FIGGR7){ref-type="fig"} ) and the tetrahedral coordination complex (*T-4*)-bis\[1-\[3-hydroxy-5-(hydroxymethyl)-2-methyl-4-pyridinyl\]-2,8,9-trioxaadamantane-3,5,7-triolato(1-)-*O* ^2^,*O* ^3'^\]zinc ([Fig. 7](#FIGGR7){ref-type="fig"}). In addition, it should be mentioned that bananin has lost most of its vitamin B~6~ character. The pyridine nitrogen is less basic than in pyridoxal and the UV parameters of pyridoxine/pyridoxal are left. Instead a typical phenolic behaviour is found and the tendency of vitamin B~6~ to exist mostly in a well-defined zwitterionic state at physiologic pH 7.4 is abandoned in bananin.Figure 5Chemical synthesis of 1-\[3-hydroxy-5-(hydroxymethyl)-2-methyl-4-pyridinyl\]-2,8,9-trioxaadamantane-3,5,7-triol. The *Knoevenagel* condensation of phloroglucinol and pyridoxal hydrochloride yields pyridoxylidenephloroglucinol. Its heat treatment with 5 M hydrochloric acid firstly produces light yellow (4′*RS*)-1′,4′-dihydrobananin. Subsequently air oxidation in the heat precipitates the orange-yellow (4′*RS*)-4′-chloro-1′,4′-dihydrobananin which results from addition of hydrogen chloride to bananin. (4′*RS*)-4′-chloro-1′,4′-dihydrobananin eliminates hydrogen chloride by treatment with strong bases (NaOH). Finally, the brown-black bananin is isolated by help of its relative insolubility in water.Figure 6Left, excerpt of the intermolecular association of black bananin leading to supramolecular chains including charge-transfer complexes between the aromatic rings and strong hydrogen-bonding between OH groups (red arrows) and the trioxa-adamantane-triol cages (magenta-green). Right, chemical structure of the yellow bananin picrate.Figure 7Proposed chemical composition of the cupric complex of bananin, the tetragonal-planar bidentate chelate (*SP-4-1*)-bis\[1-\[3-hydroxy-5-(hydroxymethyl)-2-methyl-4-pyridinyl\]-2,8,9-trioxaadamantane-3,5,7-triolato(1-)-*O*^2^,*O*^3'^\]copper \[bis(bananinato)copper, bisBNcopper\], and the zinc complex of bananin, the presumably tetrahedral bidentate chelate (*T-4*)-bis\[1-\[3-hydroxy-5-(hydroxymethyl)-2-methyl-4-pyridinyl\]-2,8,9-trioxaadamantane-3,5,7-triolato(1-)-*O*^2^,*O*^3'^\]zinc \[bis(bananinato)zinc, bisBNzinc\].

Intracellular enzymatic phosphorylation of BN to BNP by human pyridoxal kinase
------------------------------------------------------------------------------

To move a step toward the direction of possible biological activities of BN it is suggested that human pyridoxal kinase[@BIB13] accepts BN as a substrate for ATP- and Zn^2+^-dependent phosphorylation to bananin 5′-phosphate (BNP) ([Fig. 8](#FIGGR8){ref-type="fig"} ). Pyridoxal kinase can phosphorylate an array of vitamin B~6~-derivatives with modulated substituents in position 4 of the pyridine heterocycle, additionally to its natural substrates pyridoxine, pyridoxal and pyridoxamine.[@BIB14], [@BIB15] This was theoretically proofed by the crystal structure determination of sheep brain pyridoxal kinase^16^ which shows a tight binding of the 3-hydroxy-5-(hydroxymethyl)-2-methylpyridine vitamin B~6~ core structure of pyridoxal in the substrate-binding pocket, but structural fill space at the 4-position of the vitamin B~6~ core element.[@BIB16] Conclusively, it is reasonable to speculate that BN is converted into BNP by the human tissue-ubiquitous pyridoxal kinase,[@BIB13] and such is 'metabolically trapped' inside the cell after cellular uptake by vitamin B~6~ carrier systems. Through usage of vitamin B~6~ metabolic systems high intracellular concentrations of BNP could be achieved since the phosphate group-induced zwitterionic, hydrophilic appearance of BNP prevents reverse cell membrane passage.Figure 8Enzymatic intracellular phosphorylation of BN to BNP by human pyridoxal kinase resulting in 'metabolic trapping' of BNP inside the cell.

Biological significance of zinc complexation by BN for zinc ejection from HIV-1 nucleocapsid protein NCp7
---------------------------------------------------------------------------------------------------------

The HIV-1 *gag* gene polycistronic mRNA product encodes the myristoylated matrix protein p17, the phosphorylated p24 core protein, the small core peptide p2, the zinc-containing nucleocapsid protein NCp7, the small core peptide p1, and the virion-incorporated core link protein p6. NCp7 contains two highly conserved nonclassical Cys-Xaa~2~-Cys-Xaa~4~-His-Xaa~4~-Cys (CCHC) zinc finger motifs.[@BIB17], [@BIB18], [@BIB19], [@BIB20], [@BIB21], [@BIB22], [@BIB23], [@BIB24], [@BIB25], [@BIB26], [@BIB27], [@BIB28], [@BIB29], [@BIB30], [@BIB31], [@BIB32], [@BIB33], [@BIB34], [@BIB35] This retroviral zinc finger motif is conserved in all onco- and lentiretroviruses except spumaretroviruses.[@BIB23] NCp7 binds to the duplex of HIV-1 retrogenomic mRNA encapsidated in the mature virion core at the highly secondary-structured HIV-1 RNA sequence elements known as ψ-packaging signal near the 5′-LTR, next to the tRNA^Lys^ primer binding (PB) site. The two zinc fingers are sensitive to organic-chemical zinc chelating compounds. 3-Nitrosobenzamide (NOBA)[@BIB17], [@BIB18], [@BIB19] and other small molecule compounds[@BIB25], [@BIB26], [@BIB27], [@BIB28], [@BIB31], [@BIB32], [@BIB33], [@BIB35] eject zinc from NCp7 holoprotein leaving a functionally deprived apoprotein. Therefore, zinc chelators are able to inhibit HIV-1 replication and infectivity in vitro[@BIB17], [@BIB18], [@BIB19], [@BIB21], [@BIB23] and in vivo.[@BIB34] BN is an excellent zinc chelator and is postulated to be chemically suitable for zinc ejection from HIV-1 NCp7 ([Fig. 9](#FIGGR9){ref-type="fig"} ).Figure 9Postulated zinc ejection from HIV-1 (isolate HXB2) RNA-binding NCp7 holoprotein zinc finger sequence motifs I and II (yellow: [l]{.smallcaps}-cysteine, black: conserved hydrophobic [l]{.smallcaps}-amino acids, magenta: coordinatively Zn^2+^-bound [l]{.smallcaps}-histidine moieties) by four BN to yield defunctional NCp7 apoprotein, devoid of two Zn^2+^ cations, and two bisBNzinc.

Proposed active ester formation of BNP at selected RNA-viral protein RX(D/E) target sequences
---------------------------------------------------------------------------------------------

In analogy to the postulated antiviral mechanism of the retinoid vitamin A-vitamin B~6~ conjugate analogue B6RA at RGD and RLE viral protein target sequences,[@BIB12] a covalent 1,4-dihydro-4-pyridinyl active ester formation of BNP with RGD aspartic acid residues in RNA-viral protein target sequences is proposed ([Fig. 10](#FIGGR10){ref-type="fig"} ). BNP should have a similar salt-bridge amphoteric affinity to RX(D/E) protein sequence motifs like B6RA. Therefore, it could covalently bind to viral RX(D/E) sequences and, analogously to B6RA, chemically modify important viral proteins, thus making them functionally obsolete. Together with the putative antilentiviral retinoid vitamin A--vitamin B~6~ conjugate analogue B6RA, BNP is proposed to serve as effector in a system of protein target sequences RX(D/E) of RNA virus components. Human immunodeficiency virus type 1 (HIV-1) *trans*-activating transcriptional regulatory protein Tat sequences PRGDP and PRLEP were suggested as possible targets of B6RA.[@BIB12] I propose a binding of B6RA/BNP to Tat PRGDP *tat* exon 2-encoded C-terminal sequence which serves also for cross-talk with cellular tumor suppressor protein p53.[@BIB12] BNP could form an active ester at the *tat* exon 2-encoded C-terminal PRGDP sequence ([Fig. 10](#FIGGR10){ref-type="fig"}) by addition of the aspartate ([d]{.smallcaps}) residue to the trioxa-adamantane-triol 4-substituent-activated pyridine heterocycle in BNP ([Fig. 10](#FIGGR10){ref-type="fig"}). This 1,4-dihydro-4-pyridinyl active ester species would be principally able to cross-link Tat [d]{.smallcaps}-amide-like to amino groups of DNA nucleobases (adenine, guanine, cytosine) in HIV-1 proviral integrated U3/R sequences of HIV-1 5′-long terminal repeat or, more generally, in host cellular DNA. In this way, non-repairable Tat protein--DNA complexes would serve as trigger for DNA damage-induced apoptosis selectively in cells in which Tat is present. As a result the host organism would be specifically extricated from integrated HIV-1 proviruses.[@BIB12] A database search[@BIB36] and most recent status Medline/PubMed search[@BIB37] for RGD-similar sequences was performed for human RNA viruses ([Table 1](#TBL1){ref-type="table"} ). The most important human RNA virus pathogens were considered. Surprisingly, many indispensable virus proteins contain often conserved B6RA- and BNP-binding triplets RX(D/E) which are frequently surrounded by hydrophobic protein sequence strips enhancing affinity for the B6RA hydrophobic vitamin A chain ([Table 1](#TBL1){ref-type="table"}). Candidate targets of B6RA and BNP were found within proteins of RNA viruses like *Picornaviridae* (poliovirus, human coxsackievirus, hepatitis A virus), *Flaviviridae* (yellow fever virus, Dengue virus, West Nile virus, Kunjin virus, St. Louis encephalitis virus, hepatitis C virus), *Togaviridae* (rubella virus), *Coronaviridae* (human coronavirus, human SARS-associated coronavirus), *Rhabdoviridae* (rabies virus), *Paramyxoviridae* (human parainfluenza virus, measles virus, human respiratory syncytial virus), *Filoviridae* (Marburg virus, Ebola virus), *Bornaviridae* (Borna disease virus), *Bunyaviridae* (Hantaan virus), *Arenaviridae* (Lassa virus), *Reoviridae* (human rotavirus), and *Retroviridae* (HIV-1). The antiviral scope of B6RA/BNP may be related to the broad-spectrum anti-RNA-viral virustatic ribavirin[@BIB38] because ribavirin is mostly active against RNA viruses by inhibiting inosine 5′-monophosphate dehydrogenase as ribavirin 5′-monophosphate, and mRNA precursor 5′-capping as ribavirin 5′-triphosphate.[@BIB38] The actual therapeutic value of the B6RA/BNP system for chemotherapeutic treatment of RNA-viral human disease conditions remains elusive until comprehensive experimental verification is gained.Figure 10Example of a proposed covalent active ester formation of BNP at a selected, representative RNA-viral, HIV-1 *trans*-activating transcriptional regulatory Tat protein RGD sequence (see [Table 1](#TBL1){ref-type="table"}) by addition of the aspartate group to the pyridine ring of RGD-ionic contact (IC)-bound BNP resulting in an activated 1,4-dihydro-4-pyridinyl ester.Table 1Selection of RNA virus B6RA/BNP-affinity protein sequence motifs RX(D/E)VirusVirus FamilyStrainVirus ProteinB6RA/BNPSubfamilyTarget SequenceGenus**Polio type 1**PicornaviridaeMahoney, Sabin**3D**2006-FGD**RVD**YI-2013EnterovirusRNA-dependentRNAPolymerase**Polio type 2**PicornaviridaeLansing, P712**3D**2004-FGD**RVD**YI-2011EnterovirusRNA-dependentRNAPolymerase**Polio type 3**PicornaviridaeSabin vaccine**3D**2003-FGD**RVD**YI-2010EnterovirusP3/Leon/37,RNA-dependentSabin vaccineRNAP3/Leon/12a[@BIB1]b,Polymerase23127**Polio type 1**PicornaviridaeMahoney, Sabin**3D**2125-FF**RAD**EKYPFLI-2136EnterovirusRNA-dependentRNAPolymerase**Polio type 2**PicornaviridaeLansing**3D**2123-FF**RAD**EKYPFLV-2134EnterovirusRNA-dependentRNAPolymerase**Polio type 3**PicornaviridaeSabin vaccine**3D**2122-FF**RAD**EKYPFLI-2133EnterovirusP3/Leon/37,RNA-dependentSabin vaccineRNAP3/Leon/12a[@BIB1]b,Polymerase23127**Human Coxsackie A9**PicornaviridaeGriggs**3D**2113-FLKRYF**RAD**EQYPFLV-2128EnterovirusRNA-dependentRNAPolymerase**Human Coxsackie A24**PicornaviridaeEH24/70**3D**2126-FLKRFF**RAD**EKYPFLV-2141EnterovirusRNA-dependentRNAPolymerase**Human Coxsackie B1**PicornaviridaeJapan**3D**2094-FLKRYF**RAD**EQYPFLV-2109EnterovirusRNA-dependentRNAPolymerase**Human Coxsackie B3**PicornaviridaeNancy**3D**2097-FLKRYF**RAD**EQYPFLV-2112EnterovirusRNA-dependentRNAPolymerase**Human Coxsackie B4**PicornaviridaeE2, JVB / Benschoten / New York/51**3D**2095-FLKRYF**RAD**EQYPFLV-2110EnterovirusRNA-dependentRNAPolymerase**Human Coxsackie B5**Picornaviridae1954/UK/85**3D**2097-FLKRYF**RAD**EQYPFLV-2112EnterovirusRNA-dependentRNAPolymerase**Human Severe Acute Respiratory Syndrome (SARS) Corona**CoronaviridaeCoronavirusTor2, CUHK-W1, UrbaniPutative **NSP9** in ORF1ab Polyprotein RNA-dependent RNA Polymerase4470-FFKF**RVD**GDMVP-4481**Human Severe Acute Respiratory Syndrome (SARS) Corona**CoronaviridaeCoronavirusTor2, CUHK-W1, UrbaniPutative **NSP10** in ORF1ab Polyprotein Metal-binding NTPase Helicase5634-IIPARA**RVE**CFDKFKV-5649**Rabies**RhabdoviridaePasteur / PV, SAD B19**L**150-VLSCLE**RVD**YDNAF-163LyssavirusRNA-directed659-WIYYSD**RSD**LIGL-671RNAPolymerase5'-RNACappingPoly---Adenylation**Rabies**Rhabdoviridae LyssavirusPasteur / PV, SAD B19, ERA, Street, HEP-FLURY, vnukovo-32**G** Spike Membrane Glycoprotein Precursor276-LVNLHDF**RSD**EIEHLV-291**Human**ParamyxoviridaeNIH 47885,**HN**272-PKVDE**RSD**YASS-283**Parainfluenza**ParamyxovirinaeWash/1511/73,Hemagglutinin---**type 3**RespirovirusAus/124854/74,NeuraminidaseWash/641/79,Tex/545/80,Tex/9305/82,Tex/12677/83**Measles**Paramyxoviridae Paramyxovirinae MorbillivirusEdmonston, edmonston-zagreb, Halle, edmonston b, philadelphia-26, leningrad-16, Yamagata-1**F** Fusion Membrane Glycoprotein Precursor437-YPDAVYLH**RID**LGPPISL-454450-PPISLE**RLD**VGTNLG-464**Measles**Paramyxoviridae Paramyxovirinae MorbillivirusEdmonston, Rubeovax, Moraten, AIK-C, HU2, SE, Schwarz vaccine, CL, TT**M** Viral Matrix Protein186-VAFNLLVTL**RID**KAIGP-202**Human Respiratory Syncytial A**Paramyxoviridae Pneumovirinae PneumovirusA2**L** RNA-directed RNA Polymerase Protein Kinase917-Y**RGE**SLLCSLIF-928**Human Respiratory Syncytial A / B**Paramyxoviridae Pneumovirinae PneumovirusA2, Long, subgroup B/strain 18537**P** Phosphoprotein **L**/**N**-binding mRNA 5'-Capping and Polyadenylation131-ITA**RLDRID**EKLSEIL-146**Marburg**FiloviridaeMusoke, Popp**NP**558-PPPPLYAQEK**RQD**PIQHP-575FilovirusNucleocapsidMarburg virusMajorNucleoprotein**Marburg**FiloviridaeMusoke**L**1169-LLPYDCKEL**RLE**GS-1182FilovirusRNA-directed1763-ITKHDQ**RCEREE**SSP-1777Marburg virusRNAPolymerasemRNA5′-Capping andPolyadenylation**Marburg**FiloviridaeMusoke, Popp**M/VP40**262-MMKK**RGE**NSPVVYF-275FilovirusViral Matrix ProteinMarburg virus**Human Hepatitis A**Picornaviridae HepatovirusHM-175 wild type, 18F, 24A, 43C, LA, MBB**2C** Initiation of RNA Synthesis1216-AMVT**RCE**PVVCYL-1228**Yellow Fever**Flaviviridae17D,**NS5**2638-IH**RLE**PVKCDTLL-2650FlavivirusPasteurRNA-dependent3148-SVLT**RLE**AWLT-315817D-204RNAPolymerase**Dengue type 1**FlaviviridaeSingapore**NS3**2011-LMR**RGD**LPVWLSY-2023FlavivirusS275/90ProteaseNTP-BindingHelicase**Dengue type 2**FlaviviridaeJamaica, 16681,**NS3**2011-LMR**RGD**LPVWLAY-2023FlavivirusPR159/S1,Protease16681-PDK53,NTP-BindingNew Guinea-C, Tonga 1974Helicase**Dengue type 3**Flaviviridae---**NS3**2010-LMR**RGD**LPVWLAH-2022FlavivirusProteaseNTP-BindingHelicase**Dengue type 4**Flaviviridae---**NS3**2009-LMR**RGD**LPVWLSY-2021FlavivirusProteaseNTP-BindingHelicase**West Nile**FlaviviridaeWN-NY99**E/V3**370-AHNDK**RAD**PAFVC-382FlavivirusMembrane---Associated Viral EnvelopeGlycoprotein**Kunjin**FlaviviridaeMRM61C**E**370-AHNDK**RAD**PSFVC-382FlavivirusMembrane---Associated Viral EnvelopeGlycoprotein**St. Louis**FlaviviridaeMS1-7**E**368-AHNTK**RSD**PTFVC-380**Encephalitis**FlavivirusMajorEnvelopeProtein**Hepatitis C**Flaviviridae Hepacivirus1, BK, J, Taiwan, Japanese, H77, HCV-1, H, JK1, JK5, HC-JT**E2/NS1** Glycosylated Membrane Protein646-WT**RGERCD**LEDRDR-659**Rubella**TogaviridaeTherien**NSP1-2**494-CACAP**RCD**VPRERPSAP-510RubivirusNonstructuralPolyprotein5'-CapMethyltransferaseZn^2+^-CysteineProtease**Rubella**Togaviridae RubivirusTherien, HPV77 vaccine, RA27/3 vaccine**C** Structural Polyprotein Nucleocapsid Protein165-AVFY**RVD**LHFTNLGTPP-181**Human Corona**Coronaviridae229E**S/E2**94-FVYFNGTG**RGD**CKGFSSDV-112CoronavirusSurface Spike257-SVINRL**RCD**QLSFDVP-272Glycoprotein636-ALRNSA**RLE**SADVSEML-652Precursor1016-VTFVNIS**RSE**LQTIVP-1031Aminopeptidase N-binding1099-LVDLKWLN**RVE**TYIKWP-1115**Marburg**FiloviridaeMusoke, Popp**VP30**160-YLH**RSE**IGNWM-170FilovirusPhosphorylated Nucleocapsid ProteinMarburg virus**Marburg**FiloviridaeMusoke, Popp**VP24**197-FLVEVR**RID**IEPCC-210FilovirusMembrane-associated Structural ProteinMarburg virus**Ebola**FiloviridaeMayinga,**NP**103-GF**RFE**VKKRDGV-114FilovirusZaire-95,Nucleocapsid108-VKKRDGV**KRLEE**LLPAV-124Ebola virusGabon-94MajorZaireNucleoprotein**Ebola**FiloviridaeMayinga**P/VP35**292-PPVIHIRS**RGD**IPRAC-307FilovirusPolymerase Complex Protein (MinorEbola virusNucleoprotein)Zaire**Borna Disease**BornaviridaeBornavirusHe/80, He/80/FR, V, V/FR, H1766, No/98, CRNP5, CRP3A, CRP3B**P/p23**Nucleocapsid Phosphorylated P-Protein99-DISA**RIE**AGF-108116-VETIQTAQ**RCD**HSDSIR-132**Borna Disease**BornaviridaeBornavirusHe/80, He/80/FR, V, V/FR, H1766, CRNP5, CRP3A, CRP3B**N/p40**Nucleocapsid Nucleic Acid-bindingN-Protein100-YLSTPVT**RGE**QTVV-113339-YRRREIS**RGE**DGAELS-354**Hantaan**Bunyaviridae76-118, 84Fli, A16**M** Polyprotein420-VNFVCQ**RVD**MDIVVYC-435HantavirusSegment/GlycosylatedMembrane**G1** Protein**Hantaan**BunyaviridaeR22**M** Polyprotein418-ISFICQ**RVD**MDIIVYC-433HantavirusSegment/GlycosylatedMembrane**G1** Protein**Lassa**ArenaviridaeJosiah**NP** S Segment113-VI**RTE**RPLSAGVYM-126ArenavirusMajor StructuralOld WorldNucleoproteinArenavirusesNucleocapsidComponent**Lassa**ArenaviridaeGA391 Nigeria**NP** S Segment113-VT**RTE**RPLSSGVYM-126ArenavirusMajor StructuralOld WorldNucleoproteinArenavirusesNucleocapsidComponent**Human Rota**ReoviridaeKU**VP4/VP5**336-FSVS**RYE**VIKENSYVYV-352**group A**RotavirusOuter Layer482-PIMNSVTV**RQD**LERQL-497Rotavirus ASurface Protein733-YGIT**RIE**ALNLI-744HumanHemagglutinin760-PIIRN**RIE**QLILQC-773Rotavirus AFusion Protein**Human Immunodeficiency**RetroviridaeHIV-1 Reference Genome,**Tat***Trans*-activating Transcriptional1-MEPVDP**RLE**PW-11**type 1**LentivirusHTLV-III/LAV, HXB2, BRU, PV22, RF/HATRegulatoryProtein73-PTSQP**RGD**PTGP-84**Human Immunodeficiency**RetroviridaeHXB3, BH10, Clone 12**Tat***Trans*-activating Transcriptional1-MEPVDP**RLE**PW-11**type 1**LentivirusRegulatory73-PTSQS**RGD**PTGP-84Protein**Human Immunodeficiency**RetroviridaeHIV-1 Reference Genome,**Vif (Sor)**129-VSP**RCE**YQA-137**type 1**LentivirusHTLV-III/LAV, HXB2, BRU, PV22, RF/HAT, BH10, Clone 12Viral Infectivity FactorAccessoryProtein**Human Immunodeficiency**RetroviridaeHIV-1 Reference Genome,**Nef/p27**13-WPTVRERMR**RAE**PAA-27**type 1**LentivirusHTLV-III/LAV, HXB2, BRUNegative Factor100-LIHSQR**RQD**ILDLWIY-115Anti-apoptotic AccessoryProtein

Experimental
============

Synthesis of pyridoxylidenephloroglucinol from pyridoxal hydrochloride and phloroglucinol
-----------------------------------------------------------------------------------------

A mass of 20.81 g pyridoxal hydrochloride (*M*=203.63 g/mol) (*n*=102.1952 mmol) was dissolved in 63 mL water by heating on a water bath. 12.89 g phloroglucinol (*M*=126.11 g/mol) (*n*=102.2123 mmol) were dissolved in 79 mL of ethanol 90% by heating on a water bath. The two solutions were mixed and refluxed for 10 min. Then 8.59 g sodium bicarbonate (NaHCO~3~) (*M*=84.01 g/mol) (*n*=102.2497 mmol) were added to the hot yellow solution. A bright yellow precipitate formed after approximately 10 min on reflux. The suspension was additionally heated for 5 min on a water bath, cooled slowly to room temperature, and freezed to −18° C for 4 h. Then the precipitate was vacuum filtered and transferred and washed with 65 mL water. It was dried over anhydrous calcium chloride (CaCl~2~) in a vacuum desiccator. Yield: 28.1 g yellow powder (100%) pyridoxylidenephloroglucinol C~14~H~13~NO~5~ (*M*=275.26 g/mol).

Synthesis of 1-\[3-hydroxy-5-(hydroxymethyl)-2-methyl-4-pyridinyl\]-2,8,9-trioxaadamantane-3,5,7-triol (bananin) from pyridoxylidenephloroglucinol
--------------------------------------------------------------------------------------------------------------------------------------------------

28.1 g pyridoxylidenephloroglucinol (*M*=275.26 g/mol) (*n*=102.0853 mmol) were suspended in 100 mL of 5 M hydrochloric acid (500 mmol HCl). The dark yellow solution was refluxed for 15 min on a water bath. A caramel-yellow coloured precipitate of 1′,4′-dihydrobananin formed. Then it was heated to 170-180° C on an air bath and the orange-yellow (4′*RS*)-4′-chloro-1′,4′-dihydrobananin formed in the heat. When the reaction proceeds the heat is reduced to 120° C and then the mixture was cooled slowly to room temperature. Then it was freezed to −18° C for 12 h. The nearly solid orange-yellow suspension was filtered through a paper filter. The yellow-orange residue was suspended in 300 mL saturated (room temperature θ=20 °C) sodium bicarbonate (NaHCO~3~) solution in water. The orange-yellow (4′*RS*)-4′-chloro-1′,4′-dihydrobananin eliminated HCl to form bananin. Then solid sodium hydroxide (NaOH) pearls were added in small portions to the suspension until all material had dissolved to form a coffee-black solution (*V*=400 mL) of bananin sodium salt. It was titrated in small portions with 10 M hydrochloric acid until brown bananin precipitated. The chocolate brown suspension was left standing at room temperature for 3 days. After that time the suspension was filtered through a paper filter and the chocolate brown residue in the filter was washed with 400 mL water. It was dried for 2 weeks over anhydrous calcium chloride (CaCl~2~) in a vacuum desiccator. Yield: 33.2 g brown-black powder (99%) 1-\[3-hydroxy-5-(hydroxymethyl)-2-methyl-4-pyridinyl\]-2,8,9-trioxaadamantane-3,5,7-triol (bananin) C~14~H~17~NO~8~ (*M*=327.29 g/mol). IR (KBr) (wavenumber in cm^−1^): 3350 (very broad, ν O--H, s), 2900 (ν C--H, CH~3~, w), 2825 (ν C--H, CH~2~, w), 1590 (ν CC, pyridine, m), 1520 (ν CC, pyridine, m), 1430 (δ C--H, CH~2~, m), 1395 (δ C--H, CH~3~, m), 1270 (ν C--O--C, w), 1210 (ν arC--OH, m), 1110 (ν C--OH, w), 1065 (ν C--O, CH~2~OH, w), 1020 (ν C--OH, w), 900 (w), 820 (δ pyridine C--H, w), 740 (δ CH~2~, rocking, w). UV (0.1 M NaOH solution): λ~max,1~=220.0 nm \[ε=22,443 L mol^−1^ cm^−1^; *A* (1%/1 cm)=686\], λ~max,2~=285.8 nm \[ε=11,591 L mol^−1^ cm^−1^; *A* (1%/1 cm)=354\]. ^1^H NMR (CDCl~3~): δ 2.50 (s, 3H, pyridine CH~3~), 3.32 (s, 6H, CH~2~), 4.85 (m, 2H, pyridine C*H* ~2~OH), 5.90 (m, 1H, CH~2~O*H*), 8.11 (s, 1H, pyridine CH).

Qualitative preparation of amorphous 1-\[3-hydroxy-5-(hydroxymethyl)-2-methyl-4-pyridinyl\]-2,8,9-trioxaadamantane-3,5,7-triol picrate (amorphous bananin picrate)
------------------------------------------------------------------------------------------------------------------------------------------------------------------

A saturated solution (50 mL at 80° C) of 1-\[3-hydroxy-5-(hydroxymethyl)-2-methyl-4-pyridinyl\]-2,8,9-trioxaadamantane-3,5,7-triol (bananin) in dimethyl sulfoxide (DMSO) was mixed with 50 mL of a saturated (room temperature θ=20 °C) solution of picric acid (2,4,6-trinitrophenol) in 50% ethanol. Then 200 mL 90% ethanol and 500 mL water were added in the heat. A voluminous yellow precipitate formed. The temperature of the suspension was kept at −18 °C for 12 h. The precipitate was vacuum filtered and dried over anhydrous calcium chloride (CaCl~2~) in a vacuum desiccator. Yield: yellow powder of crude (bananin-containing) 1-\[3-hydroxy-5-(hydroxymethyl)-2-methyl-4-pyridinyl\]-2,8,9-trioxaadamantane-3,5,7-triol picrate (bananin picrate). Purification: the crude product was dissolved in 200 mL 5 M hydrochloric acid (1 mol HCl) by heating on a water bath and the mixture was hot filtrated. In the filter residual brown-black bananin remained. The filtrate was slowly neutralized with a solution of 40.0 g sodium hydroxide (1 mol NaOH) in 200 mL water. Yellow bananin picrate precipitated. The precipitate was vacuum filtered and dried over anhydrous calcium chloride (CaCl~2~) in a vacuum desiccator. Yield: yellow amorphous powder 1-\[3-hydroxy-5-(hydroxymethyl)-2-methyl-4-pyridinyl\]-2,8,9-trioxaadamantane-3,5,7-triol picrate (bananin picrate).

Qualitative preparation of amorphous (*SP-4-1*)-bis\[1-\[3-hydroxy-5-(hydroxymethyl)-2-methyl-4-pyridinyl\]-2,8,9-trioxaadamantane-3,5,7-triolato(1-)-*O*^2^,*O*^3'^\]copper \[bananin copper complex, bis(bananinato)copper, bisBNcopper\]
-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Suspension A: a saturated (room temperature θ=20 °C) solution of cupric sulfate pentahydrate (CuSO~4~·5H~2~O) in 100 mL of water was mixed with 100 mL of 1 M sodium hydroxide solution. Blue cupric hydroxide \[Cu(OH)~2~\] precipitated. Solution B: 50 mL of an at 80 °C saturated solution of 1-\[3-hydroxy-5-(hydroxymethyl)-2-methyl-4-pyridinyl\]-2,8,9-trioxaadamantane-3,5,7-triol (bananin) in 5 M sodium hydroxide solution. Freshly prepared suspension A was mixed with solution B and was cooled at +4 °C for 2 h. The light blue precipitate was vacuum filtered and dried over anhydrous calcium chloride (CaCl~2~) in a vacuum desiccator. Yield: dark blue amorphous powder (*SP-4-1*)-bis\[1-\[3-hydroxy-5-(hydroxymethyl)-2-methyl-4-pyridinyl\]-2,8,9-trioxaadamantane-3,5,7-triolato(1-)-*O* ^2^,*O* ^3'^\]copper \[bananin copper complex, bis(bananinato)copper, bisBNcopper\].

Qualitative preparation of amorphous (*T-4*)-bis\[1-\[3-hydroxy-5-(hydroxymethyl)-2-methyl-4-pyridinyl\]-2,8,9-trioxaadamantane-3,5,7-triolato(1-)-*O*^2^,*O*^3'^\]zinc \[bananin zinc complex, bis(bananinato)zinc, bisBNzinc\]
--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Solution A: a saturated (room temperature θ=20 °C) solution of anhydrous zinc chloride (ZnCl~2~) in 10 mL of water. Solution B: 50 mL of an at 80° C saturated solution of 1-\[3-hydroxy-5-(hydroxymethyl)-2-methyl-4-pyridinyl\]-2,8,9-trioxaadamantane-3,5,7-triol (bananin) in 5 M sodium hydroxide solution. Freshly prepared solution A was mixed with solution B and was cooled at +4° C for 2 h. The white precipitate was vacuum filtered and dried over anhydrous calcium chloride (CaCl~2~) in a vacuum desiccator. Yield: white amorphous powder (*T-4*)-bis\[1-\[3-hydroxy-5-(hydroxymethyl)-2-methyl-4-pyridinyl\]-2,8,9-trioxaadamantane-3,5,7-triolato(1-)-*O* ^2^,*O* ^3'^\]zinc \[bananin zinc complex, bis(bananinato)zinc, bisBNzinc\].
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